Xlife Sciences AG (XSWX:XLS) Return-on-Tangible-Asset: -13.74% (As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.35
GF Value CHF7.27
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Return-on-Tangible-Asset?

Xlife Sciences AG XSWX:XLS -4.38% 53 Return-on-Tangible-Asset is -13.74% as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.27 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,418 Biotechnology companies, Xlife Sciences AG ranks better than 72.71% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Xlife Sciences AG's annualized Net Income for the quarter that ended in Dec. 2025 was CHF-36.99 Mil. Xlife Sciences AG's average total tangible assets for the quarter that ended in Dec. 2025 was CHF269.21 Mil. Therefore, Xlife Sciences AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -13.74%.

The historical rank and industry rank for Xlife Sciences AG's Return-on-Tangible-Asset or its related term are showing as below:

XSWX:XLS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.06   Med: 8.12   Max: 30.62
Current: -7.98

During the past 8 years, Xlife Sciences AG's highest Return-on-Tangible-Asset was 30.62%. The lowest was -8.06%. And the median was 8.12%.

XSWX:XLS's Return-on-Tangible-Asset is ranked better than
72.71% of 1418 companies
in the Biotechnology industry
Industry Median: -35.915 vs XSWX:XLS: -7.98

Xlife Sciences AG  (XSWX:XLS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Xlife Sciences AG Return-on-Tangible-Asset Related Terms


Xlife Sciences AG Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Return-on-Tangible-Asset Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial 30.62 8.12 7.15 13.76 -8.06

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.16 0.41 26.83 -2.23 -13.74

XSWX:XLS vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Return-on-Tangible-Asset falls into.


XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Return-on-Tangible-Asset Calculation

Xlife Sciences AG's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-21.547/( (271.174+263.433)/ 2 )
=-21.547/267.3035
=-8.06 %

Xlife Sciences AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-36.994/( (274.994+263.433)/ 2 )
=-36.994/269.2135
=-13.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -13.74% mean?
Xlife Sciences AG (XSWX:XLS) has a Return-on-Tangible-Asset of -13.74% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #387 out of 1418 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Xlife Sciences AG's Return-on-Tangible-Asset too high?
Xlife Sciences AG's current Return-on-Tangible-Asset is -13.74%. Based on the distribution chart, Xlife Sciences AG ranks #387 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #387 out of 1418 companies for Return-on-Tangible-Asset. This puts Xlife Sciences AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Return-on-Tangible-Asset is -13.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.27, compared to a current price of CHF18.35 — trading 152.4% above its estimated fair value. The current Return-on-Tangible-Asset is -13.74%. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Return-on-Tangible-Asset is -13.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.35 is trading 152.4% above its estimated GF Value™ of CHF7.27. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Return-on-Tangible-Asset: -13.74%
  • GF Value™: CHF7.27 vs. price of CHF18.35 (152.4% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.35
Price
CHF7.27
GF Value